2024
Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data
Torgersen J, Mezochow A, Newcomb C, Carbonari D, Hennessy S, Rentsch C, Park L, Tate J, Bräu N, Bhattacharya D, Lim J, Mezzacappa C, Njei B, Roy J, Taddei T, Justice A, Re V. Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data. JAMA Internal Medicine 2024, 184: 943-952. PMID: 38913369, PMCID: PMC11197444, DOI: 10.1001/jamainternmed.2024.1836.Peer-Reviewed Original ResearchIncidence rateUS Department of Veterans AffairsMedication initiationDepartment of Veterans AffairsInitiation of medicationVeterans AffairsMain OutcomesPotential of medicationsOutpatient settingDischarge diagnosisCohort studyDay of admissionCase reportReal World DataReport countsMedicationMedical cohortSevere acute liver injuryUS DepartmentFollow-upAcute liver injuryHospitalCohortHepatotoxic medicationsIncidence
2023
Sa1523 ON-TREATMENT RISK OF HEPATOCELLULAR CARCINOMA DOES NOT DIFFER BY BASELINE HEPATITIS B VIRAL LOAD AMONG A LARGE COHORT OF PREDOMINANTLY NON-ASIAN PATIENTS WITH NON-CIRRHOTIC E ANTIGEN NEGATIVE CHRONIC HEPATITIS B
Yang Z, Cheung R, Jou J, Lim J, Wong R. Sa1523 ON-TREATMENT RISK OF HEPATOCELLULAR CARCINOMA DOES NOT DIFFER BY BASELINE HEPATITIS B VIRAL LOAD AMONG A LARGE COHORT OF PREDOMINANTLY NON-ASIAN PATIENTS WITH NON-CIRRHOTIC E ANTIGEN NEGATIVE CHRONIC HEPATITIS B. Gastroenterology 2023, 164: s-399-s-400. DOI: 10.1016/s0016-5085(23)01924-8.Peer-Reviewed Original Research